CourtneyKDInfanteJRLamET, et al.
Phase I Dose-Escalation trial of PT2385, a first-in-Class Hypoxia-Inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol2018;
36: 867–874.
2.
LasalaRSantoleriFRomagnoliA, et al.
Randomized clinical trials and real life studies: comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. J Oncol Pharm Pract2021; 10781552211005518.
3.
GerlingerMRowanAJHorswellS, et al.
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med2012;
366: 883–892.
4.
KaelinWG.Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer2002;
2: 673–682.
5.
ZhouLLiuX-DSunM, et al.
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene2016;
35: 2687–2697.
6.
ErbelPJACardPBKarakuzuO, et al.
Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor. Proc Natl Acad Sci U S A2003;
100: 15504–15509.
7.
ScheuermannTHTomchickDRMachiusM, et al.
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci U S A2009;
106: 450–455.
8.
ChoHDuXRizziJP, et al.
On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models. Nature2016;
539: 107–111.
9.
ChoueiriTKPlimackERBauerTM, et al.
Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol2020;
38: 611–611.
10.
JonaschEDonskovFIliopoulosO, et al.
Phase II study of the oral HIF-2α inhibitor MK-6482 for von Hippel-Lindau disease–associated renal cell carcinoma. J Clin Oncol2020;
38: 5003–5003.
11.
StrowdREEllingsonBMWenPY, et al.
Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM). J Clin Oncol2019;
37: 2027–2027.
12.
ChoueiriTKKaelinWG.Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat Med2020;
26: 1519–1530.
13.
CantorJRSabatiniDM.Cancer cell metabolism: one hallmark, many faces. Cancer Discov2012;
2: 881–898.
14.
Vander HeidenMGCantleyLCThompsonCB.Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science2009;
324: 1029–1033.
15.
MomcilovicMBaileySTLeeJT, et al.
Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer. Cell Rep2017;
18: 601–610.
16.
Tannir NM, Fan AC, Lee RJ, et al. Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). J Clin Oncol 2018; 36(6_suppl): 603–603.
17.
HannaKS.A review of checkpoint inhibitors in the management of renal cell carcinoma. J Oncol Pharm Pract off Pract2020;
26: 445–458.
18.
KhalilNSarkisJAbi TayehG.Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: lessons from CheckMate 9ER and IMmotion 151. J Oncol Pharm Pract2021.
19.
MitchellTCHamidOSmithDC, et al.
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, Open-Label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol2018;
36: 3223–3230.
20.
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018; 6(1): 57.
